TrialJournal of internal medicine2019

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.

G L Goll et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.